Premium Article - Tuesday, 06 October 2009
Europe’s highest court has ordered the European Commission to reconsider its decision that pharmaceutical company GlaxoSmithKline’s parallel pricing policy in Spain is not exempt from competition rules.
Premium Article - Tuesday, 29 September 2009
China’s Ministry of Commerce (MOFCOM) has cleared pharmaceutical company Pfizer’s acquisition of Wyeth, subject to conditions.
Premium Article - Tuesday, 29 September 2009
Europe’s competition commissioner, Neelie Kroes, today told drugmakers to expect new investigations into the pharmaceutical industry in a speech to the Committee on Economic and Monetary Affairs.
Premium Article - Monday, 28 September 2009
US pharmaceuticals company Abbott is to acquire Belgium-based Solvay’s pharmaceuticals business for €4.5 billion, the company announced today.
Premium Article - Wednesday, 16 September 2009
Eight congressmen on Monday asked the US Federal Trade Commission to reopen its investigation of pharmacy chain CVS’s 2007 merger with pharmacy benefit company Caremark.
Premium Article - Friday, 28 August 2009
The Supreme Court of New Zealand has told the Commerce Commission it overstepped its power when issuing a subpoena to AstraZeneca during an investigation of the pharmaceutical sector.
Premium Article - Thursday, 27 August 2009
A California state court has granted pharmaceutical company Bayer’s motion to dismiss an antitrust claim by indirect purchasers of its branded antibiotic Cipro.
Premium Article - Tuesday, 25 August 2009
A group of California pharmacists have filed suit in a San Francisco court in an attempt to prevent pharmaceutical companies Pfizer and Wyeth completing their US$68 billion merger.
Premium Article - Monday, 24 August 2009
US health-care provider Solaris Health Systems has filed a proposed antitrust class action alleging biotherapeutics companies CSL and Baxter International conspired to fix the price of life-saving blood plasma treatments.
Premium Article - Tuesday, 18 August 2009
Pharmaceutical companies Bayer and Barr have challenged a US Department of Justice antitrust division brief in a US appellate court, which said reverse payment settlements between brand and generic drugs companies are “presumptively unlawful”.
Premium Article - Monday, 10 August 2009
The US Federal Trade Commission has asked Watson Pharmaceuticals and its rival Arrow Group for more information about their proposed merger.
Premium Article - Thursday, 01 July 2004
Featured In: July 2004 (Vol. 7 Iss. 6)
Three companies have sought leave to bring proceedings against three major pharmaceutical companies under refusal to deal provisionsJohn Clifford McMillan Binch LLP
Premium Article - Tuesday, 01 July 2003
Featured In: July / August 2003 (Vol. 6 Iss. 7)
The Competition Butreau decided not to challenge the Fording merger in the coal sector as it was satisfied the deal was not anti-competitive; in Quebec it launched an inquiry into the local beer market; and it filed a consent agreement with the Competiton Tribunal addressing competition concerns in Pfizer/Pharmacia.Mark Opashinov and John CliffordMcMillan Binch LLPToronto
Premium Article - Monday, 01 June 1998
Featured In: June / July 1998 (Vol. 1 Iss. 3)
Parallel behaviour on prices can be very lucrative in this sector where, because of the essential nature of pharmaceuticals, demand is very stable. More often than not, demand is determined by the doctor who prescribes the medicine rather than by the consumer. The problem of proving parallel conduct has always been a topical issue in competition law. In the absence of hard evidence pointing to contact between undertakings, it is likely that the Authority will rely on the Dyestuff case, in which the ECJ stated that price increases which are very similar in timing and rate of price change cannot be explained by independent market forces.Salvatore LamarcaFreshfieldsMilan
Back to top
